Beijing Hekangyuan Biotech Co., Ltd

Beijing Hekangyuan Biotech Co., Ltd. was established on February 10, 2010 with a registered capital of CNY 4 million . It is a wholly-owned subsidiary of Zhongyi Anke Biotech Co., Ltd,The company is mainly engaged in technology development, technology transfer, technical consultation and technical services of biological products,and sale of biological products.

Since its establishment, the company has made full use of Beijing's geographical advantages and the advantages of sophisticated talents in all aspects to carry out biotechnology research.On July 11, 2012, the patent registration application of "a kit for detecting nonspecific endonuclease activity in a vaccine" was completed.On April 26, 2013, the patent application for a lyophilized protective agent for varicella vaccine containing sorbitol was jointly completed with the parent company ZhongyiAnke Biotech Co., Ltd.Meanwhile, on August 25, 2014, the patent application for « a rapid detection method of varicella virus titer » and « a production method of a new freeze-dried live attenuated varicella vaccine » were completed successively.At present, all patents have reached the stage of substansive examination.

The company purchased 800 square meters of R & D office in Beijing Economic-Technoloqical Development Area(BEIJINGETOWN), further recruited professionals, planned to establish and carry out larger-scale biological product technology R & D, consulting and transfer services, and prepared well for the sales of influenza virus subunit vaccine by parent company. ZhongyiAnke Biotech Co.,Ltd.and tetravalent meningococcal polysaccharide vaccine by Liaoning Maokangyuan Biotech Co.,Ltd.

Liaoning Maokangyuan Biotech Co., Ltd

Liaoning Maokangyuan Biotech Co., Ltd., a wholly-owned subsidiary of ZhongyiAnke Biotech Co., Ltd., was incorporated in Dongdaihe New District in November 2009 with a registered capital of 120 million yuan. It is a biopharmaceutical high-tech enterprise producing human vaccine products.Covering an area of nearly 150 mu(100,000 square meters), the company has built nearly 80000 square meters of plant facilities, including office building, staff dormitory, animal room, boiler room, warehouse and laboratory.The company has established a good cooperative relationship and extensive cooperation with the Bioengineering Institute of the Academy of Military Medical Sciences of the People's Liberation Army, one of the highest medical scientific research institutions in China.

Main R & D products: tetravalent meningococcal polysaccharide vaccine, with a designed production capacity of 5 million doses/ year (clinical approval has been obtained);Rabies vaccine for human use, with a designde production capacity of 5 million doses / year;HIB Haemophilus influenza conjugate vaccine, with a design capacity of 3 million doses/ year;Pneumonia vaccine, with a design capacity of 3 million doses / year, will be completed in 3-5 years.At the same time, the company is also cooperating with domestic and foreign scientific research institutions to develop other class I new drugs.